Lan T. Tran
Directeur Administratif chez Newfield Nutrition Corp.
Profil
Lan T.
Tran is currently the Director at Emmaus Medical Europe Ltd.
and the Secretary & Chief Administrative Officer at Newfield Nutrition Corp.
Previously, Ms. Tran held positions such as Secretary at Emmaus Medical, Inc. from 2008 to 2018, President at EMI Holding, Inc. from 2017 to 2019, and Assistant Vice President-Research Administration at Los Angeles Biomedical Research Institute at Harbor-UCLA in 2008.
Ms. Tran also served as the President & Chief Administrative Officer at Emmaus Life Sciences, Inc. from 2019 to 2021.
Ms. Tran obtained an undergraduate degree from the University of California, Los Angeles in 1999 and a graduate degree from the same institution in 2002.
Postes actifs de Lan T. Tran
| Sociétés | Poste | Début |
|---|---|---|
| Newfield Nutrition Corp. | Directeur Administratif | - |
| Emmaus Medical Europe Ltd. | Directeur/Membre du Conseil | - |
Anciens postes connus de Lan T. Tran
| Sociétés | Poste | Fin |
|---|---|---|
| EMMAUS LIFE SCIENCES, INC. | President | - |
EMI Holding, Inc.
 EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | President | 01/07/2019 |
Emmaus Medical, Inc.
 Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | Conseiller Juridique Général | 02/04/2013 |
Los Angeles Biomedical Research Institute at Harbor-UCLA
 Los Angeles Biomedical Research Institute at Harbor-UCLA BiotechnologyHealth Technology Los Angeles Biomedical Research Institute at Harbor-UCLA, also known as the Lundquist Institute, is a non-profit research organization located in Torrance, CA. The institute has also started working on a vaccine for the urgent fungal threat, Candida auris, which is spreading at an alarming rate throughout healthcare facilities in the US and is resistant to several antifungal drugs. The institute focuses on biomedical research, clinical trials, and community outreach programs. The institute has various research theme groups and researchers working on different projects, including the Institute for Translational Genomics and Population Sciences, which contributes to new research in genomics. The Lundquist Institute has received several grants and gifts for its research, including a $1.50 million gift from Farima and Joseph Czyzyk for the Diagnostic and Wellness Center. The CEO of the private company is David I. Meyer. | Corporate Officer/Principal | 01/04/2008 |
Formation de Lan T. Tran
| University of California, Los Angeles | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EMMAUS LIFE SCIENCES, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
EMI Holding, Inc.
EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | Health Technology |
Emmaus Medical, Inc.
Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | Health Technology |
Los Angeles Biomedical Research Institute at Harbor-UCLA
Los Angeles Biomedical Research Institute at Harbor-UCLA BiotechnologyHealth Technology Los Angeles Biomedical Research Institute at Harbor-UCLA, also known as the Lundquist Institute, is a non-profit research organization located in Torrance, CA. The institute has also started working on a vaccine for the urgent fungal threat, Candida auris, which is spreading at an alarming rate throughout healthcare facilities in the US and is resistant to several antifungal drugs. The institute focuses on biomedical research, clinical trials, and community outreach programs. The institute has various research theme groups and researchers working on different projects, including the Institute for Translational Genomics and Population Sciences, which contributes to new research in genomics. The Lundquist Institute has received several grants and gifts for its research, including a $1.50 million gift from Farima and Joseph Czyzyk for the Diagnostic and Wellness Center. The CEO of the private company is David I. Meyer. | Health Technology |
| Newfield Nutrition Corp. | |
| Emmaus Medical Europe Ltd. |
